| Item type |
学術雑誌論文 / Journal Article(1) |
| タイトル |
|
|
タイトル |
The Usefulness of Neoadjuvant Chemotherapy (S-1/Oxaliplatin) for Locally Advanced Mid-low Rectal Cancer |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Rectal cancer |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Neoadjuvant chemotherapy |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Prognosis |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 著者 |
Ihara, Keisuke
Nakamura, Takatoshi
Yamaguchi, Satoru
Takayanagi, Masashi
Fujita, Junki
Kono, Takahiro
Nishi, Yusuke
Shibuya, Norisuke
Hachiya, Hiroyuki
Ishizuka, Mitsuru
Muroi, Hiroto
Nakagawa, Masatoshi
Suzuki, Kan
Nakajima, Masanobu
Morita, Shinji
Ishida, Kazuyuki
Kojima, Kazuyuki
Irisawa, Atsushi
|
| 書誌情報 |
en : Dokkyo Medical Journal
巻 3,
号 4,
p. 281-288,
発行日 2024-12-25
|
| 記事種別 |
|
|
|
Original |
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: Neoadjuvant chemotherapy (NAC), which excludes radiation therapy (RT), has been investigated with the aim of lowering the local recurrence rate and suppressing distant metastasis in patients with rectal cancer, as well as avoiding the adverse events (AEs) of RT.
Aim: To clarify the therapeutic results of NAC for patients with locally advanced mid-low rectal cancer.
Materials and methods: We reviewed the data of 33 patients with stage II or III mid-low rectal cancer who underwent primary tumor resection after NAC between April 2015 and April 2018. We retrospectively analyzed the short-term treatment results, including clinicopathological factors, AEs, and perioperative complications, as well as the long-term treatment results, including the 5-year recurrence-free survival rate (RFS).
Results: The median observation period was 61.5 months (range, 29.6-97.0 months). All patients underwent SOX (S-1 + oxaliplatin) therapy. The most common AEs were thrombocytopenia in five patients (15.1%) and neutropenia in two patients (6.1%). Pathological complete response was achieved in three patients (7.8%). Recurrence was observed in six patients (18.2%), and in each case was a local recurrence event. The 5-year RFS rate was 81.8%. Multivariate analysis using the COX proportional hazards model showed that preoperative lymph node metastasis positivity (p = 0.03) and lymphatic invasion positivity (p < 0.001) were independent prognostic factors.
Conclusion: SOX therapy as preoperative chemotherapy has few adverse events and a low postoperative complication rate, and can be performed relatively safely. Because there were many local recurrences, local control with chemotherapy alone may be insufficient. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Dokkyo Medical Society |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2436-522X |
| 書誌レコードID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12941861 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.51040/dkmj.2024-007 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
DKMJ-3-4-5.pdf (125 KB)
.png)
